Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: A randomized, open-label, crossover study

Drugs and Aging

Volumn 26, Issue 2, 2009, Pages 95-101

  Darwish, Mona ^a   Xie, Fang ^a  

^a CEPHALON INC   (United States)

Author keywords

Controlled release drugs; Cyclobenzaprine, pharmacokinetics; Elderly

Indexed keywords

AMRIX; CYCLOBENZAPRINE; UNCLASSIFIED DRUG;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELDERLY CARE; EXTENDED RELEASE FORMULATION; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; IMMEDIATE RELEASE FORMULATION; MALE; MICTURITION; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; URINARY TRACT INFECTION; VOMITING; XEROSTOMIA;

AGED; AGING; AMITRIPTYLINE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 60249099169     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200926020-00001     Document Type: Article

References (14)

1. van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003; 4 (2): CD004252
2. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. J Pain Symptom Manage 2004; 28 (2): 140-75
3. Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 2003; 25 (4): 1056-73
4. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 2001; 161 (13): 1613-20
5. Nibbelink DW, Strickland SC, McLean LF, et al. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther 1978; 1 (6): 409-24
6. Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther 1988; 10 (2): 216-28
7. Nibbelink DW, Strickland SC. Cyclobenzaprine (Flexeril™): report of a postmarketing surveillance program. Curr Ther Res 1980; 28 (6): 894-903
8. Darwish M, Hellriegel ET, Xie F. Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults: a randomized, open-label, two-period crossover, single-centre study. Clin Drug Investig 2008; 28 (12): 793-801
9. Weil A, Narayana A, Chang SCK, et al. Efficacy of cyclobenzaprine hydrochloride extended-release 15 mg and 30 mg once-daily for low back and neck pain associated with muscle spasms: a pooled analysis of two randomized, double-blind, parallel-group, placebo-controlled, multicenter studies [abstract no. 206]. Pain Med 2008; 9 (1): 134-5
10. Weil AJ, Altman C, Chang SCK, et al. Efficacy of cyclobenzaprine hydrochloride extended-release 15 and 30 mg once daily for low back and neck pain associated with muscle spasm: a pooled analysis of two randomized, double-blind, parallel-group, placebo-controlled, multicenter studies [poster no. 206]. 24th Annual Meeting of the American Academy of Pain Medicine; 2008 Feb 12-16; Orlando (FL)
11. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003; 38 (8): 843-53
12. Sadean MR, Glass PS. Pharmacokinetics in the elderly. Best Pract Res Clin Anaesthesiol 2003; 17 (2): 191-205
13. Cyclobenzaprine hydrochloride tablets [package insert]. Corona (CA): Watson Laboratories, Inc., 2006
14. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects [online]. Available from URL: http://www.wma.net/e/policy/pdf/17c.pdf [Accessed 2008 Oct 10]